Aleafia to Launch Cannabis R&D Division Aleafia Labs
29 October 2018 - 10:16PM
Patient Data, Intellectual Property to be Used in
Development of Proprietary Products
Aleafia Health Inc. (
TSXV: ALEF; OTCQX: ALEAF, FRA:
ARAH) (“
Aleafia“) or (the “Company“), a
highly differentiated cannabis company with major cannabis
cultivation and medical clinic operations is formally
launching a research, development and innovation division to be
called Aleafia Labs (“
Aleafia Labs”).
Aleafia Labs will leverage the company’s existing patient
database and intellectual property to advance the development of
proprietary cannabis products. R&D activities will focus on the
development of cannabis products that may act as a replacement for
addictive prescription opioids and sleeping aids.
Dr. Gary Goodyear, Aleafia’s President of Clinic Operations, led
the Government of Canada’s research and innovation programs as the
federal Minister of State for Science and Technology. Aleafia
previously announced a medical cannabis sleep study with Cronos
Group Inc. (NASDAQ: CRON) (TSX: CRON) and expects
to announce a new biotechnology study in the near term.
“Aleafia is uniquely positioned to develop intellectual property
and commercial products following a data-driven approach,” said
President of Clinic Operations, Dr. Gary Goodyear. “While the
relationship most cannabis companies have with their patients ends
at the point of sale, our physicians closely monitor and track a
patient’s progress throughout the entire treatment cycle. This
unique data will lead to the development of innovative cannabis
products.”
“For far too long, the answer to a patient’s sleeping disorder
or chronic pain has been a prescription and a bottle of pills,”
said Aleafia Chief Medical Officer Dr. Michael Verbora. “With a
clinical approach to research and development, we will be able to
tackle some of the largest public health problems of our time.”
For Investor & Media Relations, please
contact:
Nicholas Bergamini, VP Public Affairs IR@AleafiaInc.com
About Aleafia Health Inc.:
Aleafia is a vertically integrated, national cannabis company
with major medical clinic, cannabis cultivation and R&D
operations. The company is a federally licensed producer and vendor
of cannabis and will reach an annual production capacity of 98,000
kg of dried cannabis in 2019.
Aleafia operates 22 medical cannabis clinics staffed by
physicians and nurse practitioners, with over 50,000 patients. The
company is highly differentiated, maintaining the largest medical
cannabis dataset in the world with significant intellectual
property holdings and current R&D operations.
Neither Exchange nor its Regulation Services Provider
(as that term is defined in the policies of the Exchange) accepts
responsibility for the adequacy or accuracy of this
release.
FORWARD LOOKING INFORMATION
This press release contains forward-looking statements and
information that are based on the beliefs of management and reflect
the Company's current expectations. When used in this press
release, the words "estimate", "project", "belief", "anticipate",
"intend", "expect", "plan", "predict", "may" or "should" and the
negative of these words or such variations thereon or comparable
terminology are intended to identify forward-looking statements and
information. The forward-looking statements and information
in this press release includes information relating to the
implementation of Aleafia Health's business plan. Such
statements and information reflect the current view of the Company
with respect to risks and uncertainties that may cause actual
results to differ materially from those contemplated in those
forward-looking statements and information.
By their nature, forward-looking statements involve known and
unknown risks, uncertainties and other factors which may cause our
actual results, performance or achievements, or other future
events, to be materially different from any future results,
performance or achievements expressed or implied by such
forward-looking statements. Such factors include, among
others, the following risks: risks associated with the
implementation of Aleafia Health's business plan and matters
relating thereto, risks associated with the cannabis industry,
competition, regulatory change, the need for additional financing,
reliance on key personnel, the potential for conflicts of interest
among certain officers or directors, and the volatility of the
Company's common share price and volume. Forward-looking
statements are made based on management's beliefs, estimates and
opinions on the date that statements are made and the Company
undertakes no obligation to update forward-looking statements if
these beliefs, estimates and opinions or other circumstances should
change. Investors are cautioned against attributing undue
certainty to forward-looking statements.
Aleafia Health (TSXV:ALEF)
Historical Stock Chart
From Jun 2024 to Jul 2024
Aleafia Health (TSXV:ALEF)
Historical Stock Chart
From Jul 2023 to Jul 2024